|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C14orf80 |
Gene summary for C14ORF80 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C14orf80 | Gene ID | 283643 |
| Gene name | tubulin epsilon and delta complex 1 | |
| Gene Alias | C14orf80 | |
| Cytomap | 14q32.33 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q86SX3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 283643 | C14orf80 | P1T-E | Human | Esophagus | ESCC | 2.44e-06 | 2.58e-01 | 0.0875 |
| 283643 | C14orf80 | P2T-E | Human | Esophagus | ESCC | 9.35e-10 | 2.19e-01 | 0.1177 |
| 283643 | C14orf80 | P4T-E | Human | Esophagus | ESCC | 2.45e-12 | 3.67e-01 | 0.1323 |
| 283643 | C14orf80 | P5T-E | Human | Esophagus | ESCC | 1.00e-24 | 4.73e-01 | 0.1327 |
| 283643 | C14orf80 | P8T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.29e-01 | 0.0889 |
| 283643 | C14orf80 | P9T-E | Human | Esophagus | ESCC | 2.30e-02 | 9.22e-02 | 0.1131 |
| 283643 | C14orf80 | P10T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.71e-01 | 0.116 |
| 283643 | C14orf80 | P11T-E | Human | Esophagus | ESCC | 2.46e-02 | 1.45e-01 | 0.1426 |
| 283643 | C14orf80 | P15T-E | Human | Esophagus | ESCC | 7.07e-10 | 2.34e-01 | 0.1149 |
| 283643 | C14orf80 | P16T-E | Human | Esophagus | ESCC | 1.42e-04 | 1.53e-01 | 0.1153 |
| 283643 | C14orf80 | P17T-E | Human | Esophagus | ESCC | 3.47e-14 | 5.33e-01 | 0.1278 |
| 283643 | C14orf80 | P19T-E | Human | Esophagus | ESCC | 6.53e-04 | 2.48e-01 | 0.1662 |
| 283643 | C14orf80 | P21T-E | Human | Esophagus | ESCC | 1.88e-11 | 2.22e-01 | 0.1617 |
| 283643 | C14orf80 | P23T-E | Human | Esophagus | ESCC | 4.42e-05 | 1.47e-01 | 0.108 |
| 283643 | C14orf80 | P24T-E | Human | Esophagus | ESCC | 1.97e-10 | 2.37e-01 | 0.1287 |
| 283643 | C14orf80 | P26T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.16e-01 | 0.1276 |
| 283643 | C14orf80 | P27T-E | Human | Esophagus | ESCC | 9.20e-06 | 1.88e-01 | 0.1055 |
| 283643 | C14orf80 | P28T-E | Human | Esophagus | ESCC | 6.56e-15 | 3.08e-01 | 0.1149 |
| 283643 | C14orf80 | P31T-E | Human | Esophagus | ESCC | 1.30e-15 | 3.66e-01 | 0.1251 |
| 283643 | C14orf80 | P32T-E | Human | Esophagus | ESCC | 7.28e-26 | 5.29e-01 | 0.1666 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C14orf80 | SNV | Missense_Mutation | rs782643867 | c.1094N>G | p.Val365Gly | p.V365G | Q86SX3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| C14orf80 | SNV | Missense_Mutation | c.358N>G | p.Arg120Gly | p.R120G | Q86SX3 | protein_coding | deleterious(0.05) | benign(0.321) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| C14orf80 | SNV | Missense_Mutation | c.638C>T | p.Ser213Phe | p.S213F | Q86SX3 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C8-A278-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| C14orf80 | SNV | Missense_Mutation | novel | c.845N>G | p.Pro282Arg | p.P282R | Q86SX3 | protein_coding | tolerated(0.07) | possibly_damaging(0.885) | TCGA-UU-A93S-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| C14orf80 | SNV | Missense_Mutation | rs782021817 | c.989C>T | p.Ala330Val | p.A330V | Q86SX3 | protein_coding | tolerated(0.34) | benign(0) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C14orf80 | SNV | Missense_Mutation | c.1058G>A | p.Gly353Asp | p.G353D | Q86SX3 | protein_coding | tolerated(0.33) | benign(0.116) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| C14orf80 | SNV | Missense_Mutation | rs587683388 | c.322C>T | p.Arg108Trp | p.R108W | Q86SX3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| C14orf80 | SNV | Missense_Mutation | novel | c.650N>A | p.Ala217Glu | p.A217E | Q86SX3 | protein_coding | deleterious(0) | possibly_damaging(0.461) | TCGA-CA-6715-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
| C14orf80 | SNV | Missense_Mutation | rs782038842 | c.881N>A | p.Arg294Gln | p.R294Q | Q86SX3 | protein_coding | tolerated(0.35) | benign(0.009) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| C14orf80 | SNV | Missense_Mutation | rs143331574 | c.692N>A | p.Arg231Gln | p.R231Q | Q86SX3 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AX-A1C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |